Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944616 | 0.81 | GRIN2D (0.43) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1948129 | 0.79 | GRIN2D (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1945585 | 0.77 | RAB9A (0.54) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1670668 | 0.76 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL22494493 | 0.69 | NPC1 (0.59) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8755930 | 0.68 | PLA2G2D (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL19940662 | 0.68 | EPHX1 (0.73) | SMN1; SMN2ALDH1A1EPHX1EPHX2RAB9A | |
| SCHEMBL966981 | 0.68 | EPHX1 (0.73) | SMN1; SMN2ALDH1A1EPHX1EPHX2RAB9A | |
| SCHEMBL12812331 | 0.68 | EPHX1 (0.73) | SMN1; SMN2ALDH1A1EPHX1EPHX2RAB9A | |
| SCHEMBL8394304 | 0.68 | EPHX1 (0.73) | SMN1; SMN2ALDH1A1EPHX1EPHX2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, ABCG2, TALDO1 | MEN1 2163/4885KMT2A 4464/4885SMN1; SMN2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.